Despite the variety of EGFR inhibitors, glioblastoma-targeting anti-EGFR therapy remains challenging due to the low mutational burden, specific alterations in glioblastoma, and the blood–brain barrier [11]. This evidence concerns the gene EGFR and glioblastoma.